EUCTR2008-001001-41-GB进行中（未招募）不适用
A Randomized, Double Blind, Placebo Controlled Study of the Efficacy and Safety of Angiotensin Therapeutic Vaccine (ATV) in Patients With Mild to Moderate Hypertension
Protherics Medicines Development Ltd, a BTG plc company0 个研究点开始时间: 2008年4月11日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Subjects must be competent to provide written informed consent. Subjects must sign an Institutional Review Board/Independent Ethics Committee (IRB/IEC) approved informed consent form (ICF). Authorization must also be obtained prior to the initiation of any study procedures.
- •2. Subjects must be 35-70 years of age.
- •3. Subjects must have a Body Mass Index (BMI) of 19 to 35 kg/m2, inclusive.
- •4. At baseline (Day -1), subjects must have mild to moderate hypertension as classified by the British Hypertension Society (BHS) Guidelines – BHS-IV based on the following criteria of sitting blood pressure measured by sphygmomanometry for subjects without diabetes or renal dysfunction.
- •Systolic BP (SBP)Diastolic BP (DBP)
- •Grade 1140 – 159 mmHg90 – 99 mmHg
- •Grade 2160 – 179 mmHg100 – 109 mmHg
- •5. At baseline (Day -1), all subjects must have an average sitting morning DBP 90 to 109 mmHg (inclusive) and SBP 140 to 179 mmHg (inclusive) as measured by sphygmomanometry and have responded positively to a quinapril challenge in order to enter the study. No subject will be eligible for the study if his/her SBP is >180 mmHg any time during the Screening Period.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Subjects who have failed the quinapril challenge.
- •2. Women of childbearing potential will be excluded from study participation. Women who are surgically sterile or are documented to have been post-menopausal for at least 2 years will be considered for study participation. Post-menopausal female subjects who are <60 years of age and who are not surgically sterile will be required to use a double-barrier method of birth control during the Treatment Period and Follow-up Period until their anti-angiotensin IgG titres approximates the subject’s baseline levels.
- •3. Subjects with an average sitting SBP of >180 mmHg or DBP of >110 mmHg.
- •4. Subjects with a BP difference between left and right arm on screening greater than 20 mmHg for SBP and 10 mmHg for DBP which is present on 3 consecutive readings.
- •5. Subjects with left ventricular (LV) systolic dysfunction as evidenced by a known LV ejection fraction <40% or symptomatic congestive heart failure (CHF) requiring treatment.
- •6. Subjects with a HbA1c >7.0% at Screening or a history of Type 1 or Type 2 diabetes.
- •7. Subjects who have a haemoglobin <12 g/dL at Screening.
- •8. Subjects with hypo- or hyperthyroidism, as evidenced by a serum thyroid stimulating hormone (TSH) concentration that is greater than one-times the upper limit of normal (ULN) or less than the lower limit of normal (LLN) at Screening.
- •9. Subjects with a serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2X ULN at Screening.
- •10. Subjects with other identifiable secondary causes of hypertension (eg, parathyroid disease, pheochromocytoma, Cushing’s disease, hyperaldosteronism, aortic coarctation). On Screening, if the difference between BP measured on the right and left arm is greater than 20 mmHg for SBP and 10 mmHg for DBP and are present on 3 consecutive readings, the subject will be excluded from the study.
- •11. Subjects who have experienced a myocardial infarction, unstable angina pectoris, or a cerebrovascular accident within 6 months of Screening.
- •12. Bradycardia <50 beats per minute at rest in the supine position prior to randomisation.
- •13. Subjects with sick sinus syndrome or second or third degree atrioventricular (AV) block, chronic atrial fibrillation or recurrent atrial tachyarrhythmia (including paroxysmal atrial tachycardia), a history of recurrent ventricular tachycardia, or symptomatic bradycardia.
- •14. Subjects with implanted pacemakers or an implanted cardioverter defibrillator (ICD).
- •15. Subjects with hemodynamically significant valvular heart disease.
- •16. Subjects with a history of renal dysfunction and/or estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 at Screening.18
- •17. Subjects who have had a diagnosis or recurrence of malignancy within the past 3 years, with the exception of basal cell carcinoma of the skin or in situ carcinoma of the cervix.
- •18. Subjects with sleep apnea are excluded unless a recent (within 30 days of Screening) sleep study demonstrates no recordings of arterial oxygen saturation (SaO2) <90%, treated or untreated, at any time during the Screening Period.
- •19. Subjects who perform alternating shift or night work.
- •20. Subjects not on stable doses of all concomitant medications for a minimum of 4 weeks prior to Screening, and subjects treated with any of the following prohibited medications:
- •a. Oral corticosteroids within 3 months of Screening.
- •b. Acetylsalicylic acid in excess of 325 mg per day.
- •c. Chronic stable or unstable use of non-ste
研究者
相似试验
尚未招募
3 期
Effectiveness of Bacillus Coagulans in improving appetite among patients admitted in hospitalCTRI/2018/11/016404Hindu Mission Hospital
进行中（未招募）
不适用
A Randomized, Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Thrombocytopenia in Subjects with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) - 20060198low or intermediate-1 risk MDSMedDRA version: 9.1Level: LLTClassification code 10028533Term: Myelodysplastic syndromeEUCTR2007-007258-75-ITAmgen Inc.240
已完成
不适用
Effectiveness and safety of a herbal composition to improve Aging Male SymptomsCTRI/2019/02/017506aila Neutraceuticals Pvt Ltd
招募中
3 期
A Randomized, Double Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of Aerosolized JH509 in Hospitalized Adult Patients with Mild to Moderate COVID 19COVID-19 infections diseaseJPRN-jRCT2051200159Shoji Hashimoto385
已完成
不适用
A study of Cordyceps Capsules as an Add-On Therapy in patients with moderate COVID 19 InfectioCTRI/2020/09/028131Ambrosia Food Farm Co